Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
SYRE Stock — Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. (SYRE)
Updated October 16, 2026.
SYRE is a Stock. Total return is -67.3% over the past 10.5 years, 410.0 points behind SPY at 342.7%.
Spyre Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapies for inflammatory bowel disease and rheumatic diseases, with multiple candidates in phase-2 trials targeting different inflammatory pathways either individually or in combination. The company does not currently distribute dividends. Spyre appeals primarily to investors seeking exposure to early-stage biotech development rather than those focused on income generation.
SYRE performance versus SPY
Price and return data through 2026-10-16.
Total return is -67.3% over the past 10.5 years, 410.0 points behind SPY at 342.7%. Over the past year its total return — price change plus distributions reinvested — is 259.3%. Its deepest 1-year drawdown was 27.8%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -12.4% | — |
| 3M | -15.1% | — |
| 6M | 14.6% | — |
| YTD | 143.9% | — |
| 1Y | 259.3% | — |
| 2Y CAGR | — | 57.20% |
| 3Y CAGR | — | 79.70% |
| 5Y CAGR | — | -17.10% |
| 10Y CAGR | — | -7.20% |
| Since inception (10.5 years) | -67.3% | -10.10% |
SYRE key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 04/07/2016
- Distribution frequency
- None
- Last close
- $79.90 (as of 2026-10-16)
- Market cap
- $7,466,817,197
- Average volume
- 1273321.0
- Beta
- 3.108
- Payout ratio
- 0.0%
- EPS
- $-1.92
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
SYRE risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 27.8%.
Who may consider SYRE — and who may not
It is a weaker fit for investors who need monthly cash flow (SYRE does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on SYRE
Frequently asked questions
Does SYRE pay monthly?
No. SYRE does not currently distribute.
When does SYRE pay a dividend?
SYRE does not currently distribute.
How has SYRE performed?
Total return is -67.3% over the past 10.5 years, 410.0 points behind SPY at 342.7%. Over the past year its total return — price change plus distributions reinvested — is 259.3%. Its deepest 1-year drawdown was 27.8%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.